Real-life experiences with bulevirtide for the treatment of hepatitis delta-48 weeks data from a German centre

被引：15
|
作者：
Zoellner, Caroline [1 ,2 ]
Hofmann, Joerg [3 ]
Lutz, Katrin [1 ,2 ]
Tacke, Frank [1 ,2 ]
Demir, Muenevver [1 ,2 ]
机构：
[1] Charite Univ Med Berlin, Dept Hepatol & Gastroenterol, Campus Virchow Klinikum CVK, Augustenburger Pl 1, D-13353 Berlin, Germany
[2] Campus Charite Mitte CCM,Augustenburger Pl 1, D-13353 Berlin, Germany
[3] Charite Univ Med Berlin, Inst Virol, Campus Charite Mitte, Berlin, Germany
来源：
LIVER INTERNATIONAL | 2022年 / 42卷 / 11期
关键词：
entry inhibitor; HDV therapy; real-life; VIRUS;
D O I：
10.1111/liv.15408
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
In July 2020, the entry inhibitor bulevirtide was approved in the European Union for the treatment of chronic hepatitis delta virus (HDV) infection. We describe the first 48 weeks of bulevirtide therapy in eight patients (n = 7 male, n = 1 female; n = 3 compensated cirrhosis) treated at our centre. Median ALT values declined from 82 to 34 U/L after 48 weeks. Median HDV RNA dropped from 13 380 000 to 3135 copies/ml. One patient showed no significant response and was discontinued at week 16. Overall, we observed a favourable safety profile and a marked biochemical and virological response in the majority of our patients.
引用
收藏
页码：2403 / 2407
页数：5
相关论文
共 50 条
  • [21] Results of Sunitinib Treatment of Advanced Neuroendocrine Neoplasms: 'Real-Life' Outcome Data from the German NET-Register
    Bacher, M.
    Maasberg, S.
    Fottner, C.
    Begum, N.
    Quietzsch, D.
    Skrobek-Engel, G.
    Pavel, M.
    Rinke, A.
    Lahner, H.
    Pape, U. F.
    NEUROENDOCRINOLOGY, 2015, 102 (1-2) : 127 - 127
  • [22] Clinical Outcome of Everolimus Treatment of Advanced Neuroendocrine Neoplasms: 'Real-Life' Data from the German NET-Register
    Pape, U. F.
    Bacher, M.
    Fottner, C.
    Lahner, H.
    Begum, N.
    Quietzsch, D.
    Skrobek-Engel, G.
    Pavel, M.
    Rinke, A.
    Maasberg, S.
    NEUROENDOCRINOLOGY, 2015, 102 (1-2) : 132 - 132
  • [23] MYRCLUDEX MONOTHERAPY IN COMPENSATED CIRRHOTICS WITH DELTA HEPATITIS: SAFETY AND EFFECTIVENESS BEYOND TWO YEARS OF TREATMENT IN A REAL-LIFE SETTING
    Loglio, Alessandro
    Ferenci, Peter
    Holzmann, Heidemarie
    Renteria, Sara Colonia Uceda
    Borghi, Marta
    Perbellini, Riccardo
    Rimondi, Alessandro
    Trombetta, Elena
    Giovanelli, Silvia
    Porretti, Laura
    Prati, Daniele
    Ceriotti, Ferruccio
    Lunghi, Giovanna
    Lampertico, Pietro
    HEPATOLOGY, 2020, 72 : 624A - 624A
  • [24] Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years
    Michael Auer
    Anne Zinganell
    Harald Hegen
    Gabriel Bsteh
    Franziska Di Pauli
    Klaus Berek
    Elena Fava
    Sebastian Wurth
    Thomas Berger
    Florian Deisenhammer
    Scientific Reports, 11
  • [25] Treatment of multiple sclerosis with natalizumab: experiences from a real-life cohort over 15 years
    Auer, M.
    Zinganell, A.
    Hegen, H.
    Bsteh, G.
    Di Pauli, F.
    Berek, K.
    Fava, E.
    Wurth, S.
    Berger, T.
    Deisenhammer, F.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 588 - 588
  • [26] Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years
    Auer, Michael
    Zinganell, Anne
    Hegen, Harald
    Bsteh, Gabriel
    Di Pauli, Franziska
    Berek, Klaus
    Fava, Elena
    Wurth, Sebastian
    Berger, Thomas
    Deisenhammer, Florian
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [27] Bulevirtide improves health-related quality of life measured by EQ-5D VAS in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks
    Buti, M.
    Wedemeyer, H.
    Aleman, S.
    Chulanov, V.
    Morozov, V.
    Sagalova, O.
    Stepanova, T.
    Gish, R. G.
    Lloyd, A.
    Kaushik, A. M.
    Suri, V.
    Manuilov, D.
    Osinusi, A. O.
    Flaherty, J.
    Pandey, S.
    Singh, B.
    Lampertico, P.
    DIGESTIVE AND LIVER DISEASE, 2023, 55 : S72 - S73
  • [28] Entecavir for the treatment of real-life chronic hepatitis B patients: a study from Saudi Arabia
    Al-Ashqar, Hamad Ibrahim
    Al-Quaiz, Mohammed
    Dahab, Saleim Towfeig
    Peedikayil, Musthafa Chalikandy
    ANNALS OF SAUDI MEDICINE, 2013, 33 (02) : 119 - 123
  • [29] chronic hepatitis c treatment with new generation direct-acting antivirals - real-life data from a portuguese center
    Santos, Lurdes C.
    Serrao, Rosario
    Silva-Pinto, Andre
    Faustino, Ana Sofia
    Silva, Susana
    Pitieiro, Carmelo
    Soares, Jorge
    Patricia, Andrade
    Cardoso, Helder
    Ferreira, Alcina
    Nuak, Joao
    Lopes, Susana
    Rodrigues, Susana
    Vale, Ana
    Sarmento, Antonio
    Macedo, Guilherme
    HEPATOLOGY, 2016, 64 : 993A - 993A
  • [30] Real-life efficacy of biologicals in patients with severe asthma phenotype overlap. Experiences from a tertiary pulmonary centre
    Sleiman, Y.
    Lacwik, P.
    Moscicka, A.
    Ochab-Krupnik, D.
    Palczynski, C.
    ALLERGY, 2023, 78
12345